HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS in Lung Cancer
07.03.2022 - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) - (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) ...